Fabry Disease Treatment Market 2026-2031 - Growth Driven by Increasing Adoption of Enzyme Replacement Therapy

Expanded screening is identifying more Fabry patients, while gene, mRNA and oral therapies offer less burdensome, personalized care, with strong opportunities in Asia-Pacific.


Dublin, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The "Fabry Disease Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

Fabry Disease Treatment Market to Reach USD 4.09 Billion by 2031 as Gene Therapy Innovation Accelerates

The global Fabry disease treatment market is projected to grow from USD 2.63 billion in 2025 to USD 2.83 billion in 2026. By 2031, the market is forecast to reach USD 4.09 billion, expanding at a compound annual growth rate of 7.63% between 2026 and 2031. Increasing diagnosis rates, advances in gene and mRNA therapies, broader rare disease screening programs, and sustained demand for enzyme replacement therapy are supporting market growth.

Rising Fabry Disease Prevalence Expands the Treatment Population

Reassessments of screening data indicate that Fabry disease may affect nearly one in 10,000 individuals, representing a substantially higher prevalence than earlier estimates. Late-onset forms account for a large share of symptomatic cases and may remain undetected until renal, cardiac, or other organ damage has progressed.

Expanded screening across nephrology and cardiology settings, combined with newborn testing programs in several countries, is identifying more presymptomatic patients and carriers. The resulting increase in referrals to specialty clinics is expected to strengthen long-term demand across the Fabry disease treatment market.

Gene and mRNA Therapies Reshape the Fabry Disease Pipeline

Innovation in gene therapy is creating new opportunities for potentially durable, single-dose treatments. Several adeno-associated virus-based candidates have demonstrated persistent alpha-galactosidase A expression for at least two years, with the potential to reduce infusion frequency and treatment burden.

Regulatory progress is also strengthening confidence in biomarker-driven development pathways. The accelerated approval discussions surrounding Sangamo Therapeutics' ST-920, alongside orphan designations and early clinical data for candidates such as uniQure's AMT-191 and Exegenesis Bio's EXG110, continue to attract investment. These developments could shift the market toward longer-lasting and potentially curative treatment options.

High Treatment Costs Remain a Significant Market Restraint

Despite rising clinical demand, the high cost of Fabry disease therapies continues to limit patient access. The annual cost of Elfabrio exceeds USD 430,000, placing it among the world's most expensive prescription treatments. Some insurers require evidence of organ involvement before authorizing reimbursement, which can delay therapy and affect patient outcomes.

Access challenges are particularly pronounced in emerging markets, where limited public funding and high out-of-pocket costs constrain treatment adoption. Inadequate diagnostic infrastructure also contributes to underdiagnosis and delayed care. Conversely, orphan-drug incentives, fast-track regulatory designations, and increased healthcare spending on rare diseases are expected to support future market expansion.

Enzyme Replacement Therapy Maintains Market Leadership

Enzyme replacement therapy accounted for 67.85% of Fabry disease treatment market revenue in 2025. Its established safety profile and extensive clinical use continue to support its position as a primary treatment approach. Innovation remains active within this segment, including pegunigalsidase alfa and its monthly infusion schedule, while potential biosimilar competition may increase as existing patents expire.

Gene therapy is forecast to record a 9.18% CAGR, outpacing other treatment categories as patients and clinicians seek options with lower administration burdens. Oral chaperone therapy with migalastat serves patients with amenable genetic variants, while substrate reduction therapies, including venglustat, continue to progress through clinical development. This expanding pipeline points toward a more diverse and patient-focused treatment environment.

North America Leads While Asia-Pacific Records the Fastest Growth

North America generated 42.85% of global market revenue in 2025, supported by newborn screening, specialist treatment centers, established reimbursement systems, and active clinical trial recruitment. Regulatory pathways offering priority review and breakthrough designations are also encouraging faster adoption of innovative Fabry disease therapies across the United States and Canada.

Europe remains a major market due to coordinated regulation through the European Medicines Agency, established academic registries, and strong patient advocacy networks. Although national health technology assessments may delay access, they can facilitate broad coverage once treatments receive approval. The Scottish authorization of pegunigalsidase alfa reflects continued regional uptake of new therapies.

Asia-Pacific is projected to be the fastest-growing regional market, with an 8.28% CAGR. Japan's early-access framework, South Korea's insurance coverage for enzyme replacement therapy, and China's expanded rare disease reimbursement policies are accelerating treatment availability. Growing clinical trial activity and healthcare infrastructure investment in India and Southeast Asia are expected to create additional opportunities through 2031.

Key Topics Covered:

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Fabry Disease
4.2.2 Advancements in Gene- and mRNA-Based Therapies
4.2.3 Favorable Orphan-Drug Incentives and Fast-Track Designations
4.2.4 Increasing Global Healthcare Expenditure on Rare Diseases
4.2.5 Strategic Collaborations and Licensing Agreements
4.2.6 Expansion of Telemedicine and Home-Infusion Services
4.3 Market Restraints
4.3.1 High Treatment Costs and Payer Budget Constraints
4.3.2 Limited Diagnostic Infrastructure in Emerging Markets
4.3.3 Manufacturing Capacity Constraints for Advanced Therapies
4.3.4 Stringent Reimbursement Criteria and Access Barriers
4.4 Regulatory Landscape
4.5 Porter's Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)
5.1 By Treatment
5.1.1 Enzyme Replacement Therapy
5.1.2 Oral Chaperone Therapy
5.1.3 Gene Therapy
5.1.4 Substrate Reduction Therapy
5.1.5 Other Treatments
5.2 By Route of Administration
5.2.1 Intravenous
5.2.2 Oral
5.2.3 Subcutaneous
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Specialty Pharmacies
5.3.4 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.4.3.1 GCC
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
6.3.1 Sanofi (Genzyme)
6.3.2 Takeda Pharmaceutical
6.3.3 Amicus Therapeutics
6.3.4 Chiesi Farmaceutici
6.3.5 Protalix BioTherapeutics
6.3.6 JCR Pharmaceuticals Co., Ltd.
6.3.7 ISU ABXIS
6.3.8 Freeline Therapeutics
6.3.9 Yuhan Corporation
6.3.10 M6P Therapeutics
6.3.11 AVROBIO
6.3.12 Sangamo Therapeutics
6.3.13 4D Molecular Therapeutics
6.3.14 Idorsia
6.3.15 BioMarin Pharmaceutical
6.3.16 Orchard Therapeutics
6.3.17 Moderna Tx
6.3.18 Ultragenyx
6.3.19 Rocket Pharmaceuticals

7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/825yhi

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Kontaktdaten

GlobeNewswire